Stock 605507 GUOBANG PHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guobang Pharma Ltd.

Equities

605507

CNE100004NS2

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/06/2024 BST 		5-day change 1st Jan Change
17.24 CNY +2.99% Intraday chart for Guobang Pharma Ltd. -1.32% -1.82%
04-15 Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01-27 Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The group's high margin levels account for strong profits.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 13.36 for the current year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUOBANG PHARMA LTD. Stock Guobang Pharma Ltd.
-1.82% 1.28B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.22% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 654B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.44% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+22.03% 337B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.75% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 229B
A+
NOVARTIS AG Stock Novartis AG
+13.03% 219B
B-
AMGEN INC. Stock Amgen Inc.
+9.64% 171B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 605507 Stock
  4. Ratings Guobang Pharma Ltd.